Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) shows potential for upside based on Wall Street analysts' short-term price targets, with a mean target of $46.45 indicating a 27% upside from the current price of $36.59 [1] Price Targets and Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $8.02, indicating variability among analysts; the lowest estimate is $32.00 (12.5% decline), while the highest is $62.00 (69.5% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates - Analysts are optimistic about HRMY's earnings prospects, as indicated by a positive trend in earnings estimate revisions; the Zacks Consensus Estimate for the current year has increased by 7.4% with no negative revisions [11][12] - HRMY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates; thus, investors should approach price targets with skepticism [8][10] - Despite the skepticism surrounding price targets, the direction implied by them may still provide a useful guide for potential price movements [14]

Core Viewpoint - TTM Technologies (TTMI) shows potential for significant upside, with a mean price target of $118.5 indicating a 26.4% increase from the current price of $93.77 [1] Price Targets - The average price target ranges from a low of $108.00 to a high of $126.00, with a standard deviation of $8.58, suggesting a consensus among analysts [2] - The lowest estimate indicates a 15.2% increase, while the highest suggests a 34.4% upside [2] Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about TTMI's earnings prospects, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price movements [11] - Over the last 30 days, three estimates have been revised upward, leading to a 14.2% increase in the Zacks Consensus Estimate [12] Zacks Rank - TTMI holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Price Movement Guidance - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movements [14]

Core Viewpoint - Credo Technology Group Holding Ltd (CRDO) is experiencing positive momentum with a projected revenue increase and a bullish price target set by Roth Capital, indicating strong investor interest and market activity. Group 1: Price Target and Stock Performance - Roth Capital has set a price target of $200 for CRDO, suggesting a potential increase of about 62.06% from the current stock price of $123.41 [1][5] - The current stock price of CRDO is $123.41, reflecting a 10.78% increase or $12.01 from the previous trading session [3][5] - Over the past year, CRDO's stock has experienced significant volatility, with a high of $213.80 and a low of $29.09 [3][5] Group 2: Revenue Expectations - Credo has announced preliminary revenue results for the third quarter of fiscal year 2026, expecting to report revenue between $404 million and $408 million, which exceeds previous expectations [2][5] - The updated revenue guidance for the fourth quarter of fiscal year 2026 may be influencing current trading activity and investor interest [4] Group 3: Market Capitalization and Trading Activity - Credo's market capitalization is approximately $22.29 billion, indicating a substantial presence in the market [4] - The trading volume for CRDO today is 7,059,246 shares, reflecting active investor interest [4]

Core Viewpoint - Karooooo Ltd. (KARO) has shown a 6.2% increase in stock price over the past four weeks, with a mean price target of $60.25 indicating a potential upside of 25.7% from the current price of $47.92 [1] Price Targets - The average price target consists of four estimates ranging from $60.00 to $61.00, with a standard deviation of $0.5, suggesting a relatively high agreement among analysts [2] - The lowest estimate indicates a 25.2% increase, while the highest suggests a 27.3% upside [2] Analyst Consensus and Earnings Estimates - Analysts have shown increasing optimism regarding KARO's earnings prospects, as evidenced by a strong agreement in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 7%, with two estimates moving higher and no negative revisions [12] - KARO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][10] - Price targets can be influenced by analysts' business incentives, leading to potentially inflated estimates [8] - A low standard deviation among price targets indicates a high degree of agreement among analysts, which can serve as a starting point for further research [9]

Core Viewpoint - AngioDynamics (ANGO) shares have shown a slight increase of 0.1% over the past four weeks, closing at $10.06, with analysts suggesting a potential upside of 92.2% based on a mean price target of $19.33 [1] Price Targets and Analyst Consensus - The average price target for ANGO ranges from a low of $16.00 to a high of $24.00, with a standard deviation of $4.16, indicating a potential increase of 59.1% to 138.6% from the current price [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a positive indicator for investors [2][9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ANGO's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 3.6% over the past month, with no negative revisions, indicating positive sentiment [12] Zacks Rank and Investment Potential - ANGO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [13]

Core Viewpoint - TAL Education (TAL) shares have increased by 8.2% over the past four weeks, closing at $12.25, with a mean price target of $15.59 indicating a potential upside of 27.3% [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $2.15, where the lowest estimate is $11.54 (5.8% decline) and the highest is $18.00 (46.9% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [2][9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about TAL's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 74%, with three estimates moving higher and no negative revisions [12] Zacks Rank and Investment Potential - TAL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of TAL's potential gains, the implied direction of price movement appears to be a useful guide [14]

Core Viewpoint - Sunrun (RUN) shares have shown a modest increase of 0.9% over the past month, closing at $18.47, with analysts suggesting a potential upside of 25.3% based on a mean price target of $23.14 [1] Price Targets and Analyst Estimates - The mean estimate consists of 20 short-term price targets with a standard deviation of $2.72, indicating variability among analysts; the lowest estimate is $19.00 (2.9% increase), while the highest is $30.00 (62.4% increase) [2] - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding Sunrun's earnings prospects, as indicated by a significant increase in earnings estimate revisions, which correlates with potential stock price movements [11] - The Zacks Consensus Estimate for the current year has surged by 469.7% over the past month, with no negative revisions, indicating strong positive sentiment [12] Zacks Rank and Investment Potential - Sunrun currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a useful guide for potential price movements [14]

Core Viewpoint - SkyWest (SKYW) shares have shown no change over the past four weeks, closing at $101.47, but analysts suggest a potential upside of 26.5% based on a mean price target of $128.33 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $12.55, indicating variability among analysts [2] - The lowest estimate is $112.00, suggesting a 10.4% increase, while the highest estimate is $150.00, indicating a potential surge of 47.8% [2] - A smaller standard deviation reflects greater agreement among analysts regarding price movement [2][9] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, three earnings estimates have increased, leading to a 3.1% rise in the Zacks Consensus Estimate [12] - SkyWest holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][10] - Price targets can be influenced by business relationships, leading to potentially inflated estimates [8][9]

Group 1 - The stock of Bitdeer Technologies Group (BTDR) closed at $12.96, reflecting an 8.3% gain over the past four weeks, with a mean price target of $29.73 indicating a potential upside of 129.4% [1] - The mean estimate consists of 11 short-term price targets with a standard deviation of $7.04, where the lowest estimate is $14.00 (an 8% increase) and the highest is $40.00 (a 208.6% increase) [2] - Analysts show strong agreement on BTDR's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for BTDR's current year earnings has increased by 29.3% over the past month, with no negative revisions [12] - BTDR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does suggest a positive direction for price movement [14]

Core Viewpoint - Humana Inc. is experiencing stock price fluctuations and mixed signals from analysts and investors, indicating a complex outlook for the company in the health insurance sector [1][2][5]. Group 1: Analyst Insights - Morgan Stanley has set a price target of $174 for Humana, suggesting a potential decrease of approximately -10.86% from the current trading price of $195.20 [1][5]. - The stock has shown volatility, with a trading range today between $192.40 and $197.34, and over the past year, it has reached a high of $315.35 and a low of $191.39 [4]. Group 2: Investor Activity - Tejara Capital Ltd has acquired 7,200 shares of Humana, valued at around $1.87 million, indicating confidence in the company's long-term potential despite a slight decrease in stock price [2][5]. - Other hedge funds, such as Elevation Point Wealth Partners LLC and Mather Group LLC, have made new investments in Humana, with positions valued at approximately $32,000 and $34,000, respectively [3][5]. - Private Wealth Management Group LLC increased its holdings in Humana by 47.5% in the third quarter, now owning 149 shares valued at $39,000 [3]. Group 3: Market Metrics - Humana's market capitalization is approximately $23.48 billion, with a trading volume of 3,220,371 shares on the NYSE [4].